The FDA has accepted Gilead Sciences’ new drug application for lenacapavir as a long-lasting injectable to prevent HIV ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

RANI READ THE FULL RANI RESEARCH REPORT On February 5 th , Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shared its preclinical readout from the RT-116 study demonstrating successful oral delivery of ...

Opdivo-Qvantig had a non-inferior objective response rate compared to intravenous formulation in patients with locally ...

She started treatment with etanercept (Enbrel ®) 1 month previously. One day after a subcutaneous injection into the left thigh, she developed a mildly pruritic eruption on the right thigh ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Results of a placebo-controlled trial support prior observational findings that GLP-1 agonists can help reduce alcohol ...

Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the FDA, making treatment easier for patients and potentially adding years to the product's patent life.

Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% ...

The Dec. 27, 2024, Food and Drug Administration (FDA) approval of the subcutaneous injection formulation of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for patients with solid tumors opened up ...